[Prevalence and prognostic significance of anti-HTLV-I and anti-HIV-2 antibodies in patients with HIV infection in the Roman region]

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

[Prevalence and prognostic significance of anti-HTLV-I and anti-HIV-2 antibodies in patients with HIV infection in the Roman region]

Boll Ist Sieroter Milan. 1988;67(5-6):345-50. Unique Identifier : AIDSLINE MED/91299260
Antinori A; Tamburrini E; Ventura G; Nervo P; Ortona L; Universita Cattolica del Sacro Cuore, Facolta di Medicina e; Chirurgia, Instituto di Clinica delle Malattie Infettive, Roma.

Abstract: A chronic coinfection with CMV, EBV etc. has been described in patients with HIV infection; recently a coinfection with other retroviruses has been described too. We have looked for the presence of antibodies to HTLV-I (anti HTLV-I) and to HIV-2 (anti HIV-2) in 135 HIV infected (HIV-positive) subjects living in Rome. They were 100 i.v. drug addicts, 24 homo/bisexuals, 4 partners of HIV-positive patients, 5 polytransfused and 2 without any known risk factor; 32 of them had a full-blown AIDS, 52 had ARC and 51 were symptom-free. Anti HIV, anti HTLV-I and anti HIV-2 were detected with ELISA method and confirmed by Western Blot (W.B.) technique. Antibodies to HTLV-I were found in 14 cases (10.4%) and antibodies to HIV-2 in 12 cases (8.9%). The contemporary presence of anti HIV, anti HTLV-I and anti HIV-2 was not found in any subjects. Our data fail to show a clear relationship among the coinfection with different retroviruses and the various risk factors for HIV infection and the HIV-related clinical picture (AIDS, ARC, etc.).

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Adolescence Adult Aged AIDS-Related Complex/IMMUNOLOGY Comparative Study Cross-Sectional Studies English Abstract Female Human HIV Antibodies/*BLOOD HIV Infections/*COMPLICATIONS/EPIDEMIOLOGY/IMMUNOLOGY HIV-1/IMMUNOLOGY HIV-2/*IMMUNOLOGY HTLV-BLV Antibodies/*BLOOD HTLV-BLV Infections/*COMPLICATIONS/EPIDEMIOLOGY/IMMUNOLOGY HTLV-I/*IMMUNOLOGY Male Middle Age Prognosis Risk Factors Rome/EPIDEMIOLOGY JOURNAL ARTICLE
911030
M91A1110

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .